Published on : May 24, 2016
ALBANY, New York, May 24, 2016: The study, titled “Global Non-Hematological Cancers Market to 2021 - Strong growth driven by increased uptake of low toxicity targeted treatments and versatile biologics,” offers a detailed analysis of the market, focusing on the present clinical and commercial scenario by considering diagnosis, disease pathogenesis, prognosis, and the treatment preferences which are available at every stage of diagnosis. According to the research study, in 2014, the global market for non-hematological cancers was valued at US$73 bn and is estimated to reach a value of US$141 bn by the end of 2021. The market is projected to register a 9.86% CAGR between 2015 and 2021.
The research report further analyzes the pipeline of non-hematological cancer and distinguishes it on the basis of the development stage, molecule type, and molecular target, with a detailed breakdown across the major indications. It also studies the growth in patient epidemiology and presents the market revenues for the global non-hematological cancer market as well as the leading players.
Click here to get more info with TOC in a PDF Format: https://www.researchmoz.us/enquiry.php?type=S&repid=716914
In the last few years, the risk of cancer has increased significantly among the patients over the age of 65. Since the global population is expected to increase substantially along with rising cases of obesity, growing geriatric population, the prevalence of cancer as a genetic disorder is projected to increase, resulting in the augmented growth of the global non-hematological cancers market. In 2012, there were around 32 mn people who were living with some type of cancer in the span of five years of diagnosis. The non-hematological cancers represented 94% of global cancer prevalence. The major cancer indications of this research study, such as colorectal, prostate, breast, and lung cancer, accounted for nearly 51% of global cancer prevalence.
The research study further analyzes the composition of the non-hematological cancer market on the basis of each indication, in terms of leading molecule targets and types, emphasizing the major commercial assets and market players. In the last few years, there have been substantial developments in formulating targeted therapies for cancer patients. These therapies are less-toxic and can thus be administered to a large number of cancer patients more frequently. In addition, the introduction of these treatments is anticipated to enhance the survival rate of those patients who have not been exhibiting adequate improvement.
Furthermore, the research study talks about the composition of the therapeutic pipeline in the market and which drugs are expected to achieve the status of blockbuster. At present, there are 6,484 oncology products in the overall pipeline. The pipeline development landscape, clinical trials, and final approval of drugs have been included in the scope of the research report. Some of the leading players operating in the global market for non-hematological cancers are Bristol-Myers, Novartis, Pfizer, Astellas, Amgen, and Roche.
To order report Call USA – Canada Toll Free: 866-997-4948 or send an email on email@example.com